Drug Search Results
Using advanced filters...
Advanced Search [+]

ZP-120

Alternative Names: zp-120, zp120, zp 120
Latest Update: 2022-07-01
Latest Update Note: PubMed Publication

Product Description

a novel ligand of the nociceptin/orphanin FQ (N/OFQ) peptide receptor, NOP. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12237257/)

Mechanisms of Action: NOP Agonist

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Zealand Pharma
Company Location: COPENHAGEN G7 00000
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Heart Failure, Acute|Heart Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2004-004801-11

P2

Completed

Heart Failure, Chronic|Heart Failure, Acute

2025-01-30

Recent News Events